## **REMARKS**

## Election/Restrictions

In response to the Restriction Requirement dated December 11, 2007, Applicants elect Group I, claims 1-8 drawn to methods for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation comprising administering an inhibitor.

For the species, we designate Compound (I) disclosed on page 6 of the specification, namely: 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide having the formula I

Further from Claim 1, Applicants designate the species c-Kit from the list in claim 1.

From claim 3, Applicants designate the compound 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide.

With regard to Claim 6, Applicants designate the disease being Alzheimer's.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7898

Date: February 4, 2008

Lydia T. McNally
Attorney for Applicant

Reg. No. 36,214